ReShape Lifesciences Inc.
- Jurisdiction
United States - ISIN
US76090R4083 (RSLS )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. Read full profile
Fundamentals
- Net revenue
€5.50M - Gross margin
62.6% - EBIT
-€5.74M - EBIT margin
-104.3% - Net income
-€3.84M - Net margin
-69.7%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Earnings Calls
Latest earnings call: May 15, 2024 (Q1 2024)